[go: up one dir, main page]

EA201391758A1 - Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты - Google Patents

Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты

Info

Publication number
EA201391758A1
EA201391758A1 EA201391758A EA201391758A EA201391758A1 EA 201391758 A1 EA201391758 A1 EA 201391758A1 EA 201391758 A EA201391758 A EA 201391758A EA 201391758 A EA201391758 A EA 201391758A EA 201391758 A1 EA201391758 A1 EA 201391758A1
Authority
EA
Eurasian Patent Office
Prior art keywords
spronged
heart
pharmaceutical composition
composition containing
organic acids
Prior art date
Application number
EA201391758A
Other languages
English (en)
Inventor
Элина Харонски
Дафна Ариели
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201391758A1 publication Critical patent/EA201391758A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Описана спрессованная сердцевина для фармацевтической лекарственной формы, содержащая смесь (a) по меньшей мере одной фармацевтически приемлемой органической кислоты и (b) по меньшей мере одного фармацевтически приемлемого эксципиента. Такая спрессованная сердцевина пригодна для получения фармацевтических композиций, содержащих лекарственное средство, где растворимость лекарственного средства повышается в кислотных условиях. Также описаны фармацевтические композиции, содержащие такую спрессованную сердцевину.
EA201391758A 2011-05-24 2012-05-24 Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты EA201391758A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161489511P 2011-05-24 2011-05-24
PCT/US2012/039327 WO2012162492A1 (en) 2011-05-24 2012-05-24 Compressed core comprising organic acids for a pharmaceutical composition

Publications (1)

Publication Number Publication Date
EA201391758A1 true EA201391758A1 (ru) 2014-06-30

Family

ID=46201864

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391758A EA201391758A1 (ru) 2011-05-24 2012-05-24 Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты

Country Status (5)

Country Link
US (1) US20120301541A1 (ru)
JP (1) JP2014517843A (ru)
EA (1) EA201391758A1 (ru)
IL (1) IL229473A0 (ru)
WO (1) WO2012162492A1 (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
ES2673286T3 (es) 2011-02-11 2018-06-21 Zx Pharma, Llc Formulaciones multiparticuladas de L-mentol y métodos relacionados
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
CA2844367C (en) * 2011-06-24 2016-02-16 Acenda Pharma, Inc. Method and improved pharmaceutical composition for improving the absorption of an ester prodrug
DE102011078825B4 (de) 2011-07-07 2018-07-19 Sauer Gmbh Lasertec Verfahren und Laserbearbeitungsmaschine zur Bearbeitung eines Werkstücks
SMT202100608T1 (it) 2012-02-21 2021-11-12 Towa Pharmaceutical Europe S L Composizioni farmaceutiche orali di dabigatran etexilato
AU2013229990B2 (en) * 2012-03-07 2017-07-06 Santarus, Inc. Controlled-release solid dosage forms of mesalamine
CA2877774C (en) 2012-07-12 2017-07-18 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
EP2740471B1 (en) * 2012-12-07 2015-05-27 Hexal AG Oral pharmaceutical composition comprising dabigatran etexilate
CN103127109B (zh) * 2013-02-05 2014-08-13 南京华威医药科技开发有限公司 含达比加群酯或其盐和水合物的药用组合
ES2706152T3 (es) 2013-04-23 2019-03-27 Zx Pharma Llc Composición entérica de múltiples partículas revestida con subrevestimiento proteico
CN103230378B (zh) * 2013-05-10 2014-12-10 青岛双鲸药业有限公司 一种氯雷他定片的制备方法
CN104414995A (zh) * 2013-09-04 2015-03-18 天津汉瑞药业有限公司 甲磺酸达比加群酯的药用组合物
WO2017111637A1 (en) 2015-12-23 2017-06-29 Zaklady Farmaceutyczne Polpharma Sa Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof
WO2018229784A1 (en) * 2017-06-14 2018-12-20 Natco Pharma Limited Pharmaceutical compositions of dabigatran
IL319158A (en) 2017-09-11 2025-04-01 Atossa Therapeutics Inc Methods for preparing and using endoxifen
WO2020032885A2 (en) * 2018-05-04 2020-02-13 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Capsule-in-capsule compositions of dabigatran etexilate
JP2020147542A (ja) * 2019-03-14 2020-09-17 日本ケミファ株式会社 ダビガトランエテキシラートまたはその薬学的に許容される塩を含有する多層錠
JP2020180099A (ja) * 2019-04-26 2020-11-05 沢井製薬株式会社 ダビガトランエテキシラートメタンスルホン酸塩製剤
MX2022000203A (es) * 2019-07-03 2022-03-22 Atossa Therapeutics Inc Composiciones de liberacion sostenida de endoxifeno.
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
DE3124090A1 (de) * 1981-06-19 1983-01-05 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale dipyridamolformen
DE3627423A1 (de) * 1986-08-13 1988-02-18 Thomae Gmbh Dr K Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung
AU748359B2 (en) * 1998-05-15 2002-06-06 Chugai Seiyaku Kabushiki Kaisha Controlled-release formulations
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
SI1485094T2 (sl) * 2002-03-07 2020-08-31 Boehringer Ingelheim International Gmbh Farmacevtska oblika za oralno dajanje etil estra 3((2-((4-(heksiloksikarbonilamino-imino-metil)-fenilamino)-metil)-1- metil-1H-benzimidazol-5-karbonil)-piridin-2-il-amino)-propionske kisline ali njegovih soli
EP1633358A1 (en) * 2003-05-20 2006-03-15 Pfizer Products Inc. Pharmaceutical compositions of varenicline
DE10337697A1 (de) 2003-08-16 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
US20050107438A1 (en) 2003-09-03 2005-05-19 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore
US20050241656A1 (en) * 2004-04-27 2005-11-03 Chr. Hansen A/S High flavor load particle and method of preparing same
DE102005020002A1 (de) 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005025728A1 (de) 2005-06-04 2006-12-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester
GB0517205D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
WO2008019712A1 (de) * 2006-08-18 2008-02-21 Evonik Röhm Gmbh Pharmazeutische zusammensetzung mit kontrollierter wirkstoffabgabe für wirkstoffe mit guter löslichkeit in wasser
WO2008043759A1 (en) 2006-10-10 2008-04-17 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006054005A1 (de) 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
EP2090297A1 (en) * 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin

Also Published As

Publication number Publication date
US20120301541A1 (en) 2012-11-29
WO2012162492A1 (en) 2012-11-29
JP2014517843A (ja) 2014-07-24
IL229473A0 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
EA201391758A1 (ru) Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
ZA201608614B (en) Solid oral pharmaceutical compositions for isoxazoline compounds
CY1120342T1 (el) Ανταγωνιστης πολυκυκλικου lpa1 και χρησεις εξ' αυτου
NZ627274A (en) Anesthetic compounds and related methods of use
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
EA201490228A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
EA201491671A1 (ru) Гетероциклильные соединения
MY183588A (en) New salvianolic acid compound l, preparation method and use thereof
EA201190161A1 (ru) Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения
NZ703162A (en) Heterocyclic modulators of lipid synthesis
EP2581376A4 (en) MATRINIC ACID / MATRINE DERIVATIVES AND METHODS OF PREPARATION AND USES THEREOF
EA201591195A1 (ru) Новые хинолоновые производные
EA201592144A1 (ru) Производное фенола, способ его получения и его применение в медицине
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
IN2012DE00337A (ru)
EA201590697A1 (ru) Производные кетамина
EA201290659A1 (ru) Новая композиция ретигабина
EA201490395A1 (ru) Способ получения фармацевтических композиций, содержащих финголимод
CL2013002129A1 (es) Compuestos derivados de acido 3-heteroaroilamino-propionico sustituidos, como inhibidores de la proteasa catepsina a; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso para el tratamiento de insuficiencia cardiaca, enfermedades inmunologicas, asma, dolor, entre otras.
WO2014036502A3 (en) Tetracycline compounds
EA201590797A1 (ru) Препараты с модифицированным высвобождением опрозомиба
EA201291014A1 (ru) Трициклическое индазольное соединение, способ его получения и содержащая его фармацевтическая композиция
EA201391124A1 (ru) Новые бензодиоксолпиперазиновые соединения
EA201490573A1 (ru) Соединение бензотиазолона